Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 8/20 | 0.51 |
| ▸ | RAMP1 | O60894 | 7/20 | 0.51 |
| ▸ | ADM2 | Q7Z4H4 | 10/20 | 0.50 |
| ▸ | CALCB | P10092 | 9/20 | 0.49 |
| ▸ | CALCA | P06881 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13015187 | 0.85 | CALCRL (0.38) | CALCRLRAMP1ADM2CALCB | |
| SCHEMBL24220794 | 0.83 | CALCA (0.50) | CALCRLRAMP1ADM2CALCBCALCA | |
| SCHEMBL1700141 | 0.83 | CALCA (0.50) | CALCRLRAMP1ADM2CALCBCALCA | |
| SCHEMBL27308573 | 0.83 | CALCA (0.52) | CALCRLRAMP1ADM2CALCBCALCA | |
| SCHEMBL10246001 | 0.82 | CALCRL (0.51) | CALCRLRAMP1ADM2CALCBCALCA | |
| SCHEMBL15935551 | 0.81 | CALCRL (0.36) | CALCRLRAMP1ADM2CALCBCALCA | |
| SCHEMBL13015182 | 0.81 | CALCRL (0.38) | CALCRLRAMP1ADM2CALCB | |
| SCHEMBL12622804 | 0.81 | ADM2 (0.54) | CALCRLRAMP1ADM2CALCB | |
| SCHEMBL13671264 | 0.81 | CALCA (0.50) | CALCRLRAMP1ADM2CALCBCALCA | |
| SCHEMBL549390 | 0.81 | CALCA (0.50) | CALCRLRAMP1ADM2CALCBCALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796260-B2 | Imidazobenzazepine CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20100324023-A1 | IMIDAZOBENZAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100324023-A1 | IMIDAZOBENZAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324023-A1 | IMIDAZOBENZAZEPINE CGRP RECEPTOR ANTAGONISTS | BDKRB1, CCKBR, CALCRL | CALCRL 3/4885RAMP1 53/4885ADM2 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.